Press releaseGlobe Newswire
Conexeu Sciences
CNXU · NASDAQ
$2.99+$0.00 (+0.00%)TodayMarket closed ·
Prev close $2.99
Latest news
- Press releaseGlobe Newswire
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
- News
Conexeu Sciences Issues Update On Regulatory And Manufacturing Program Supporting Planned FDA 510(k) Premarket Notification For Ten Minute Tissue, Lead Wound Care Device Candidate
- Press releaseGlobe Newswire
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission
- Press releasePRNewswire
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
- Press releaseGlobe Newswire
Conexeu Sciences Sets September and October 2026 Conference Schedule
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- Press releaseGlobe Newswire
The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.
- Press releaseGlobe Newswire
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
- Press releaseGlobe Newswire
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Press releaseGlobe Newswire
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- Press releaseGlobe Newswire
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
- Press releaseGlobe Newswire
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.
- Press releaseGlobe Newswire
A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
- Press releaseGlobe Newswire
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
- Press releasePRNewswire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- Press releasePRNewswire
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It
- Press releaseGlobe Newswire
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Press releaseGlobe Newswire
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
- Press releaseGlobe Newswire
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
- Press releaseGlobe Newswire
Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself
- Press releaseGlobe Newswire
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
- Press releasePRNewswire
Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Press releaseGlobe Newswire
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
- Press releasePRNewswire
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
- Press releaseGlobe Newswire
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- Press releaseGlobe Newswire
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.